Islet allografting in the dog model: potential therapies for tolerance induction.
Brons
I G
IG
Department of Surgery, University of Cambridge, Addenbrookes Hospital, UK.
Davies
H F
HF
Rasmussen
A
A
Watson
C J
CJ
Thiru
S
S
Cobbold
S P
SP
Waldmann
H
H
Calne
R Y
RY
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D015703:Antigens, CD / Q000276:immunology; D001786:Blood Glucose / Q000378:metabolism; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D018958:CD55 Antigens; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D003169:Complement Inactivator Proteins / Q000276:immunology; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000628:therapy*; D004285:Dogs; D006085:Graft Survival; D007165:Immunosuppression Therapy / Q000379:methods*; D016381:Islets of Langerhans Transplantation / Q000276:immunology* / Q000502:physiology; D017493:Leukocyte Common Antigens / Q000276:immunology; D008562:Membrane Glycoproteins / Q000276:immunology; D010180:Pancreatectomy; D054562:Protein Tyrosine Phosphatase, Non-Receptor Type 1; D014184:Transplantation, Homologous
D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D001786:Blood Glucose; D018958:CD55 Antigens; D003169:Complement Inactivator Proteins; D008562:Membrane Glycoproteins; D017493:Leukocyte Common Antigens; D054562:Protein Tyrosine Phosphatase, Non-Receptor Type 1